GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure

Patients with breast or ovarian cancer have not benefited from improved efficacy with pegylated liposomal doxorubicin relative to free drug, likely due to the limited extent of the enhanced permeability and retention (EPR) effect, further compromising drug bioavailability in the tumor. Herein it is...

Full description

Bibliographic Details
Main Author: Fonseca, Nuno A. (author)
Other Authors: Gregório, Ana C. (author), Mendes, Vera M. (author), Lopes, Rui (author), Abreu, Teresa (author), Gonçalves, Nélio (author), Manadas, Bruno (author), Lacerda, Manuela (author), Figueiredo, Paulo (author), Pereira, Marta (author), Gaspar, Manuela (author), Colelli, Fabiana (author), Pesce, Daniela (author), Signorino, Giacomo (author), Focareta, Laura (author), Fucci, Alessandra (author), Cardile, Francesco (author), Pisano, Claudio (author), Cruz, Tony (author), Almeida, Luís (author), Moura, Vera (author), Simões, Sérgio (author), Moreira, João N. (author)
Format: article
Language:eng
Published: 2021
Subjects:
Nucleolin
Targeted-drug delivery
Mesothelioma
Breast cancer
Nucleolin-overexpressing cancers
Online Access:http://hdl.handle.net/10316/93834
Country:Portugal
Oai:oai:estudogeral.sib.uc.pt:10316/93834

Internet

http://hdl.handle.net/10316/93834

Similar Items